GCRF_NF55 Fast-track vaccine cold-chain assessment and design for mass scale COVID-19 vaccination in Bangladesh (VaCoBD)

普遍获得疫苗是低收入国家目前面临的一项重大挑战，主要原因是缺乏健全的冷链，导致25%以上的疫苗失去效力。全球COVID-19大规模疫苗接种将需要一种新的快速通道方法来评估、重新设计和建立现有的冷链物流资产和系统，以前所未有的规模和速度交付疫苗。我们的目标是评估孟加拉国冷链框架作为COVID-19大规模疫苗接种案例研究国家的能力和准备情况，并协助政策制定者确定优化的可持续干预措施和持久的遗留机会。我们的目标是：(1)评估孟加拉国冷链和资源的背景和弹性，收集主要数据，以对冷链能力和差距进行强有力的评估；(2)在现有物流基础设施和配送系统的基础上，开发自下而上的整体系统方法，用于大规模COVID-19疫苗接种，包括模式转移；(3)为自下而上（疫苗）系统模型制定成本效益分析框架；(4)评估COVID-19大规模疫苗接种准备的不同干预方案，并帮助制定国家免疫战略和重点；(5)向政策制定者和其他主要利益攸关方（包括货币金融机构）通报用于COVID-19大规模疫苗接种冷链开发的具有成本效益的干预备选方案，这些备选方案可能对未来的紧急情况或灾害有用；(6)向其他国家传播经验，包括方法，以评估其需求并模拟在流行病和自然灾害中为卫生和医疗用品建立可持续温控供应链的最佳选择。

Universal vaccine access is an existing major challenge in low-income countries, mainly due to the lack of robust cold-chains, resulting in loss of potency for +25% of vaccines. Mass vaccination for COVID-19 globally will require a new fast-track approach to assess, re-engineer and build upon available cold-chain logistics assets and systems, to deliver the vaccines at scale and speed never before considered. We aim to evaluate the capacity and preparedness of the cold-chain framework of Bangladesh as a case study country for mass scale COVID-19 vaccination, and assist the policymakers in defining optimised, sustainable interventions and lasting legacy opportunities. Our objectives are: (1) evaluating the context and resilience of cold-chains and resources in Bangladesh, collecting primary data for a robust assessment of the cold chain capacity and gaps; (2) developing a bottom-up whole systems approach building upon existing logistics infrastructure, and distribution systems for mass scale COVID-19 vaccination including modal shifts; (3) developing a cost-benefit analysis framework for the bottom-up (vaccine) systems model; (4) assessing different intervention scenarios for mass-scale COVID-19 vaccination preparedness, and helping shape the country's immunisation strategies and priorities; (5) informing policymakers and other key stakeholders, including Monetary Financial Institutions about the cost-effective intervention alternatives for cold-chain development for mass-scale vaccination for COVID-19, which may be useful for future emergency or disasters; and (6) disseminating learnings to other countries, including methodology, to assess their requirements and to simulate best options for creating sustainable temperature-controlled supply-chains for health and medical supplies in epidemics and natural disasters.